Home > Yann-Alexandre Vano, ESMO 2020 – Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor in Naive Metastatic Kidney Cancer: The BIONIKK Trial
Genitourinary Cancers, Renal Cancer

Yann-Alexandre Vano, ESMO 2020 – Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor in Naive Metastatic Kidney Cancer: The BIONIKK Trial

Published Online: October 1st 2020
Authors: Yann-Alexandre Vano

Dr Yann-Alexandre Vano joins touchONCOLOGY to discuss the role of personalization of treatment in kidney cancer, and the major findings from the BIONIKK trial investigating nivolumab and ipilimumab as a first-line therapy for patients with kidney cancer. The late-breaking abstract ‘Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR tyrosine Kinase inhibitor (TKI) in naïve metastatic Kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial’(LBA25) was presented at the Virtual 2020 ESMO Congress in September 2020.

Questions

  1. In which metastatic kidney cancer patients is nivolumab and ipilimumab indicated as first-line therapy, and what are the limitations of its use? (0:06)
  2. What were the aims and design of the BIONIKK trial? (2:00)
  3. What were the major findings of the trial? (3:49)
  4. What will be the impact of these findings on future personalization of treatment according to tumour molecular characteristics in kidney cancer? (6:06)
  5. What unanswered questions remain in the use of nivolumab and ipilimumab, and what future studies are planned? (8:30)

Speaker Disclosures: Yann-Alexandre Vano  has nothing to disclose in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. The BIONIKK trial was sponsored by Association pour la Recherche des Thérapeutiques Innovantes en Cancérologie – Bristol Myers Squibb.

Filmed in coverage of the Virtual 2020 ESMO Congress.

Share this Video
Related Videos In Renal Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar